Lipids and eicosanoids in fibrosis: emerging targets for therapy
- PMID: 22810365
- DOI: 10.1097/BOR.0b013e328356d9f6
Lipids and eicosanoids in fibrosis: emerging targets for therapy
Abstract
Purpose of review: Lipid mediators including the lysophospholipids, sphingolipids and eicosanoids have long been implicated in inflammation, cancer and numerous other diseases. Over the last decade, new research suggests a role for these mediators in fibrosis.
Recent findings: Recent developments in the study of fibrotic mediators have centered on lysophospholipids and eicosanoids. New research is evaluating metabolic-profiling strategies to quantitatively measure lipid mediators in human plasma. Lysophosphatidic acid receptor antagonists are currently under development with early phase trials scheduled for idiopathic pulmonary fibrosis and scleroderma dermal fibrosis. Eicosanoids have long been implicated in maintaining tissue homeostasis, and the balance of profibrotic and antifibrotic effects has drawn attention in recent years. Targeting the prostanoids, specifically PGE2 and PGI2, as well as the leukotrienes is now being considered for antifibrotic therapies.
Summary: Lipid mediators have significant roles in many disease processes. Significant research now suggests a critical role for these mediators in the pathogenesis of fibrosis. Targeting these mediators is a promising area of drug discovery.
Similar articles
-
First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor.Arch Pharm Res. 2012 Jun;35(6):945-8. doi: 10.1007/s12272-012-0600-2. Arch Pharm Res. 2012. PMID: 22870802
-
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.Eur Respir Rev. 2024 Jun 12;33(172):240015. doi: 10.1183/16000617.0015-2024. Print 2024 Apr. Eur Respir Rev. 2024. PMID: 39009409 Free PMC article. Review.
-
Understanding modulations of lipid mediators in cancer using a murine model of carcinomatous peritonitis.Cancer Med. 2022 Sep;11(18):3491-3507. doi: 10.1002/cam4.4699. Epub 2022 Mar 22. Cancer Med. 2022. PMID: 35315587 Free PMC article.
-
Druggable Lysophospholipid Signaling Pathways.Adv Exp Med Biol. 2020;1274:137-176. doi: 10.1007/978-3-030-50621-6_7. Adv Exp Med Biol. 2020. PMID: 32894510 Review.
-
Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?Chest. 2008 Jun;133(6):1442-1450. doi: 10.1378/chest.08-0306. Chest. 2008. PMID: 18574287 Free PMC article. Review.
Cited by
-
Metabolite Alterations in Autoimmune Diseases: A Systematic Review of Metabolomics Studies.Metabolites. 2023 Sep 1;13(9):987. doi: 10.3390/metabo13090987. Metabolites. 2023. PMID: 37755267 Free PMC article. Review.
-
Diallyl disulfide inhibits proliferation and transdifferentiation of lung fibroblasts through induction of cyclooxygenase and synthesis of prostaglandin E₂.Mol Cell Biochem. 2014 Aug;393(1-2):77-87. doi: 10.1007/s11010-014-2048-9. Epub 2014 Apr 23. Mol Cell Biochem. 2014. PMID: 24756243
-
Epithelial Cells and Inflammation in Pulmonary Wound Repair.Cells. 2021 Feb 5;10(2):339. doi: 10.3390/cells10020339. Cells. 2021. PMID: 33562816 Free PMC article. Review.
-
Understanding Metabolomics in Biomedical Research.Endocrinol Metab (Seoul). 2016 Mar;31(1):7-16. doi: 10.3803/EnM.2016.31.1.7. Endocrinol Metab (Seoul). 2016. PMID: 26676338 Free PMC article. Review.
-
Evolving Perspectives on Innate Immune Mechanisms of IPF.Front Mol Biosci. 2021 Aug 9;8:676569. doi: 10.3389/fmolb.2021.676569. eCollection 2021. Front Mol Biosci. 2021. PMID: 34434962 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
